This review is a summary of two head-to head studies; risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): placebo and ustekinumab-controlled phase 3 trials.
Commentary is provided by Professor Richard Langley, Professor and Director of Research in the Division of Dermatology, Department of Medicine at Dalhousie University in Canada, and was President of the Canadian Dermatology Association in 2014, and Dr Diana Rubel, a consultant dermatologist in private practice at Woden Dermatology, Canberra, and a visiting medical officer and Senior Lecturer at The Canberra Hospital and Australian National University.
Please login below to download this issue (PDF)